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Ki-67, a marker of cellular proliferation, is increasingly being used in pre-surgical window studies in endometrial
cancer as a primary outcome measure. Unlike in breast cancer, however, there are no guidelines standardizing
its measurement and its clinical relevance as a response biomarker is undetermined. It is, therefore, imperative
that Ki-67 scoring protocols are optimized and its association with patient survival rigorously evaluated, in order
to be able to clinically interpret the results of these studies. Using the International Ki-67 in Breast Cancer
Working Group guidelines as a basis, whole slide, hot spot and invasive edge scoring protocols were evaluated
using endometrial biopsies and hysterectomy specimens from 179 women. Whole sections and tissue
microarrays, manual and semi-automated scoring using Definiens Developer software were additionally
compared. Ki-67 scores were related to clinicopathological variables and cancer-specific survival in uni- and
multivariate analysis. Against criteria of time efficiency, intra- and inter-observer variability and consistency,
semi-automated hot spot scoring was the preferred method. Ki-67 scores positively correlated with grade, stage
and depth of myometrial invasion (P-values all o0.03). By univariate analysis, higher Ki-67 scores were
associated with a significant reduction in cancer-specific survival (P≤ 0.05); however, this effect was
substantially attenuated in the multivariate model. In conclusion, hot spot scoring of whole sections using
Definiens is an optimal method to quantify Ki-67 in endometrial cancer window study specimens. Measured this
way, it is a clinically relevant marker, though further work is required to determine whether reductions in Ki-67 in
neoadjuvant intervention studies translate into improved patient outcome.
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Despite the rising incidence and corresponding
increase in deaths from endometrial cancer, there is
a noticeable lack of research into new prevention
and treatment strategies.1,2 There is a dearth of high
quality clinical trial evidence to inform the manage-
ment of women with advanced or recurrent endo-
metrial cancer. Similarly, there is a lack of robust
evidence to guide the clinical care of women who are
unfit for surgery or who desire fertility-sparing
treatment.
Clinical trials require large numbers of partici-
pants over long follow-up periods to demonstrate the
superiority of one treatment over another on
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clinically important outcomes, such as overall and
cancer-free survival. In cancer types that are amen-
able to diagnostic sampling, novel interventions can
be screened for efficiently using the pre-surgical
window study design, whereby tissue endpoints are
compared before (at diagnosis) and after treatment (at
definitive surgery) using biomarkers as surrogates for
clinical endpoints. Ideally such biomarkers should
have prognostic utility and be able to predict
response to adjuvant treatment and longer term
outcome.3 Their use allows the rapid screening of
new interventions so that time, effort, and financial
resources can be directed at treatments that hold the
most promise.
Window studies in endometrial cancer are ham-
pered by the lack of validated biomarkers meeting
these criteria. In breast cancer, the nuclear protein
Ki-67 is an established prognostic and predictive
biomarker.4–6 Expressed only during the active G1, S,
and G2 phases of the cell cycle, its expression is a
marker of cellular proliferation and is readily
detected by immunohistochemistry.7 The Interna-
tional Ki-67 in Breast Cancer Working Group set
standards for the staining, scoring and analysis of Ki-
67 in breast cancer to ensure the reproducibility,
reliability and accuracy of studies using Ki-67 as
their primary outcome measure.8 In brief, these
included:
 Sole use of the MIB-1 antibody with heat-induced
epitope retrieval
 Inclusion of positive and negative controls in all
batches
 Scoring at least three high-power fields (×40
magnification) across whole sections, incorporat-
ing the invasive edge of the tumor and hot spots
 Assessment of nuclear staining only (intensity of
staining not relevant)
 Counting at least 500 (and preferably 1000)
malignant cells
 Expressing the Ki-67 score as the percentage of
positively stained cells among the total number of
malignant cells assessed
Despite ambiguity in the literature about the value
of Ki-67 as a biomarker in endometrial cancer, pre-
surgical window studies using a change in Ki-67 as
their primary endpoint have begun in earnest.9–13
Although Ki-67 expression has been shown to
positively correlate with tumor grade,12,14–16 there
is a lack of consensus as to whether it has prognostic
value.14–18 Heterogeneity of staining, scoring, and
analysis protocols, including the use of study-
specific cut-off values, have also hampered the
validation of findings in other cohorts and, by
extension, hindered the clinical interpretation of
results from the aforementioned window studies.
Furthermore, most previous studies were published
over 10 years ago, using the now superseded FIGO
1988 staging criteria, limiting their applicability to
modern clinical research.17,18
The aims of this study were three-fold: to identify
the most reliable, reproducible and time efficient
method of Ki-67 scoring using the recommendations
of the International Ki-67 in Breast Cancer Working
Group as a guide;8 to determine the correlation
between Ki-67 and known pathological prognostic
variables; and to investigate whether higher Ki-67
expression is associated with a shorter cancer-
specific survival and, therefore, has clinical value
as a biomarker in endometrial cancer trials.
Materials and methods
Patient and Tissue Selection
The study was designed, analyzed, and reported in
accordance with the REMARK guidelines for tumor
marker prognostic studies.19 Tumor tissues from 179
patients undergoing hysterectomy for endometrial
cancer were retrospectively selected. This included
128 consecutive patients who had donated tissue for
research to the Manchester BRC Biobank from 2009
to 2014. Due to a preponderance of low grade and
stage disease in this cohort, an additional 51 high-
risk patients, for whom tissue and clinical follow-up
data were available, were included from partner
institutions of the TransPORTEC consortium (Leiden
University Medical Center, The Netherlands; Uni-
versity Medical Center Groningen, The Netherlands;
University College London, United Kingdom; and
Gustave Roussy Paris, France) to ensure a represen-
tative population. This latter group included patients
who had undergone primary surgery between 1991
and 2010. All grades, stages, and histological
subtypes of endometrial cancer were included. All
patients underwent surgery. Patients with intermedi-
ate or high-risk disease were given adjuvant treat-
ment according to local protocols.
Tumor from hysterectomy specimens and, for a
subset of tumors, corresponding endometrial biop-
sies taken immediately before the start of surgery,
were formalin fixed and paraffin embedded, and
stored at room temperature for up to 24 years. Four-
μm thick sections were cut from representative
paraffin blocks using a cryostat and mounted onto
a histological glass slide. Slides were either stained
immediately or stored at +4 °C pending immunohis-
tochemistry. Whole hematoxylin and eosin-stained
slides were reviewed by experienced gynaecological
histopathologists (JB, RM, and TB) to confirm FIGO
(2009) stage, histological subtype, grade, depth of
myometrial invasion and the presence or absence of
lymphovascular space invasion. Tissue microarrays
were created by the study histopathologists from
hysterectomy specimens for a subset of the Manche-
ster patients and the transPORTEC cohort using
triplicate tumor cores. This allowed the effect of
slide preparation technique to be determined by
comparing Ki-67 scores from whole sections and
tissue microarrays obtained from the same tumor.
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Immunohistochemistry
Immunohistochemistry was performed using the
Leica Bond Max (Leica Biosystems, Wetzlar, Ger-
many) with heat-induced epitope retrieval. This fully
automated system is routinely used in many hospi-
tals and ensures consistent staining across runs.
Staining was performed using the optimized proto-
col recommended by the International Ki-67 in
Breast Cancer Working Group.8 Antigen retrieval
was undertaken at pH 9 for 20min. A casein block of
30min duration was carried out to reduce non-
specific antibody binding. Slides were incubated at
room temperature for 1 h with the MIB-1 antibody
(monoclonal mouse, anti-human Ki-67 antibody;
DAKO, Carpinteria, CA), at a dilution of 1:100.
Primary antibody detection was undertaken using
the Refine Detection Kit (Leica Biosystems), which
contains a rabbit anti-mouse IgG secondary antibody
and anti-rabbit poly-HRP IgG antibody and utilizes
3,3′-diaminobenzidine as a chromogen. Slides were
counterstained with hematoxylin. Negative (isotype
control) and positive (tonsil) controls were used for
quality assurance.
Ki-67 Scoring
Slides were digitized using the Leica SCN400 Slide
Scanner (Leica Microsystems, Wetzlar, Germany). A
semi-automated score was obtained by applying a
computerized algorithm (Definiens Developer) to the
malignant glands (Figure 1a and b). Manual selection
of malignant glands guaranteed that scoring was
limited to these areas and that stromal and inflam-
matory cells were excluded. In the case of carcino-
sarcomas, only malignant glands (the carcinoma
component) were selected for scoring. Manual
selection of malignant glands was repeated prior to
each application of the algorithm. Malignant glands
were visually compared prior to and following
application of the Definiens Developer solution to
ensure the correct classification of nuclei as posi-
tively and negatively stained and that debris and
artifact were reliably excluded. All stained nuclei
were counted as positive, irrespective of staining
intensity. Different algorithms were tried and their
accuracy checked for whole section and tissue
microarray analyses, although similar rules and
thresholds applied. For each algorithm, the accuracy
of nuclei detection was confirmed using a subset of
12 randomly selected slides. For whole slides, the
Ki-67 proliferation index, referred to hereafter as the
Ki-67 score, was the percentage of positively stained
nuclei scored according to three methods: whole
slide, hot spot, and invasive edge scoring. For
manual scoring, the percentage of positively stained
nuclei within three high-powered fields (×40 magni-
fication) randomly selected across the tumor was
calculated, ensuring at least 1000 nuclei were
counted. Using the semi-automated system, all
nuclei within three (hot spot and invasive edge) or
five (whole slide) representative high-powered fields
(×20) were scored (at least 2000 nuclei in total). The
areas to be scored were selected randomly across the
section to take into account the heterogeneous
proliferation seen in endometrial tumors (whole
slide scoring), from areas of maximal Ki-67 staining
(hot spot scoring) or from the endometrial/myome-
trial interface (invasive edge scoring) by two inde-
pendent scorers (SK and VS), who were blinded to
patient outcome (Figure 1c–h). For the tissue micro-
arrays, all malignant glands of each tumor core were
scored in their entirety.
Individual tumor cores and full sections were
scored three times (twice by SK, once by VS) and the
final Ki-67 score was calculated as the mean value of
the three repeats. For the tissue microarrays, the final
Ki-67 score for each tumor was the average of nine
measurements; three cores from each tumor scored
on three separate occasions. Discordant results of
410% (between SK and VS) were settled by
consensus. The time to score individual slides was
measured using a stopwatch.
Follow-up Data Collection
Demographic, pathology, and follow-up data were
obtained from electronic and hard copy patient
records. In Manchester, patients were reviewed in
specialist clinics every 4 months for the first two
years and six monthly thereafter for a total of five
years. The detection of recurrent disease was by way
of symptom enquiry and clinical examination, with
imaging as required. Cause of death was determined
from primary care and mortuary records. For the
transPORTEC patients, clinical follow-up data were
provided by individual clinicians and stored in a
secure database. All cases without events were
censored at the last follow-up visit.
Statistical Analysis
Tumor availability and consent for follow-up data
collection limited the sample size to 179 patients;
similar numbers to previous studies of Ki-67 in
endometrial cancer.14,15,18 Importantly, this cohort
included 26 endometrial cancer-related deaths and
41 recurrences, ensuring that the study was ade-
quately powered to investigate the effect of Ki-67 on
endometrial cancer recurrence and survival.19
Ki-67 was measured as a continuous score using
the hot spot method and data conformed to a
negatively skewed distribution (Figure 2). Intra-
and inter-observer variability was assessed by intra-
class correlation coefficient. Bland–Altman plots
were constructed to compare scores from endome-
trial biopsies and corresponding hysterectomy speci-
mens and different slide preparation techniques,
with 95% limits of agreement interpreted clinically.
The association between Ki-67 and other pathologi-
cal and clinical variables was tested using the
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Mann–Whitney U-test for non-parametric data and
Spearman rank correlation for continuous and
ordinal variables. Kaplan–Meier curves were con-
structed to estimate cancer-specific survival
according to Ki-67 score and the log-rank test for
trend used to compare curves. Cancer-specific
survival was defined as the time between date of
surgery and death from endometrial cancer.
Recurrence-free survival was the interval between
date of surgery and first documentation of recurrent
disease. A Cox proportional hazard regression model
was used in uni- and multivariate analyses of cancer-
specific and recurrence-free survival, after confirm-
ing that the data complied with the proportional
hazards assumption using log–log curves. These
analyses examined Ki-67 as a continuous variable,
using 10% increments to derive hazard ratios. The
univariate analysis included previously documented
important co-variates; age, body mass index
(o30 kg/m2 vs ≥ 30 kg/m2), grade (1, 2, and 3), stage
(1, 2, 3, and 4), histological type (endometrioid vs
non-endometrioid), lymphovascular space invasion
(presence vs absence), depth of myometrial invasion
(o50% vs ≥50%), and adjuvant therapy use (yes vs
no). The multivariate analysis utilized the significant
Figure 1 Ki-67 immunohistochemistry and scoring using Definiens Developer on whole sections and tissue microarrays. The accuracy of
the solution to correctly identify individual positively and negatively stained nuclei was manually checked by comparing individual
endometrial cancer glands with and without the solution applied. (a) Photomicrograph of endometrial cancer gland with Ki-67
immunohistochemistry applied (b) digital scoring output (×20 magnification). Positively stained nuclei are yellow, negatively stained
nuclei are blue. (c) Representative tissue microarray core following Ki-67 immunohistochemistry. (d) Same tissue microarray core
following the application of Definiens Developer solution, with endometrial cancer glands shown in orange and the surrounding stroma in
dark blue. Areas of the slide without the presence of tissue are colored pale blue. (e) Whole section of tumor following Ki-67
immunohistochemistry. Compared with the tissue microarray, a significantly greater tumor area is present on a whole section and is a
better representation of the heterogeneity in proliferation seen across endometrial cancers. (f) The same section of tumor with the five areas
selected at random using Definiens Developer software highlighted in orange to determine the whole slide score. (g) Three areas of greatest
proliferation identified to provide a hot spot score. (h) Three areas along the endometrial/myometrial interface to quantify the invasive
edge score.
Figure 2 Frequency distribution of Ki-67 scores, as measured by
the hot spot scoring method in 179 patients. The median Ki-67
score was 40%, with an interquartile range of 24–52%.
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prognostic variables identified in the univariate
analysis. The model was developed using forward
stepwise regression and confirmed using backward
stepwise regression. Both methods produced iden-
tical results. A P-value of ≤ 0.05 was regarded as
being of statistical significance. The statistical ana-
lysis was carried out using SPSS version 22 and
GraphPad Instat.
Results
Optimization of Ki-67 Scoring
The semi-automated platform, combined with whole
slide and hot spot scoring methods, demonstrated
excellent intra- and inter-observer agreement, com-
parable to that seen with manual scoring (Table 1).
The intra-class correlation coefficient values of
0.906–0.962 correspond to ‘almost perfect’ agree-
ment between repeated measurements by the same
and different observers. Invasive edge scoring, in
contrast, had lower reproducibility (intra-class cor-
relation coefficient 0.750–0.868) and could only be
performed on the 50% of available slides in which
the endometrial/myometrial interface was sampled,
limiting the value of this scoring method. Semi-
automated scoring was considerably more time
efficient than manual scoring, saving over 4min
per slide (2.2–3.1min vs 7.7min).
Whole slides and tissue microarrays from the same
tumor were available for a subset of the Manchester
patients (n=17) and 50 of the 51 TransPORTEC
patients. In general, there was poor agreement
between whole slide and tissue microarray scores
for individual patients (Figure 3a and Table 2),
particularly when slides had been cut at the same
time but stained several months apart. Delayed
staining (of 3 months or more) resulted in much
lower Ki-67 scores (data not shown). Within tissue
microarrays, there was substantial variation in scores
between individual cores from the same tumor and
between observers (inter-observer intra-class correla-
tion coefficient 0.701).
As the window study design necessitates analysis
of tumor tissue prior to and following pre-surgical
intervention, the consistency of Ki-67 scores across
different tumor sampling techniques is important.
Scores determined using the whole slide scoring
method and Definiens software varied significantly
between endometrial biopsies taken immediately
prior to surgery and the corresponding hysterectomy
specimen (Figure 3b, 95% limits of agreement − 18 to
+38%). Hot spot scoring (Figure 3c) was more
consistent, with the exception of a single outlier,
which, when removed, reduced the 95% limits of
agreement to –7 to 13%. On the basis of these
findings, hot spot scoring was deemed the optimal
scoring method and was applied in survival analyses
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Clinical Relevance of Ki-67
The cohort included 116 endometrioid and 63
non-endometrioid type (including serous, clear cell,
carcinosarcoma, mixed, and undifferentiated)
cancers, of which 108 were FIGO stage 1 (60%), 22
were stage 2 (12%), 42 were stage 3 (24%), and 6
were stage 4 (3%). The estimated median follow-up
time, using the reverse Kaplan–Meier method, was
39.5 months, during which time 41 (23%) patients
had local (22, 12%) and/or distant recurrences
(35, 20%). There were 47 deaths (26%), of which
26 (15%) were from endometrial cancer. For grade
1/2 endometrioid, grade 3 endometrioid and non-
endometrioid type cancers, 5-year cancer-specific
survival rates were 93%, 88%, and 43%
(Po0.0.001), respectively.
The median Ki-67 score in the overall cohort was
40%, with an interquartile range of 24–52%. The
relationship between Ki-67 and patient clinicopatho-
logical characteristics was investigated (Table 3).
As expected, Ki-67 score was closely associated with
tumor grade (P≤0.001). In addition, it was also
positively correlated with patient age, stage, depth of
myometrial invasion, and adjuvant therapy use
(P-values all ≤0.04). Scores were higher in those
tumors with lymphovascular space invasion present
and non-endometrioid histology, though these
results did not reach statistical significance.
Ki-67 scores were divided into two equal groups
using the median score of 40% to denote low and
high expression, to explore the relationship between
Ki-67 and cancer-specific survival. The Kaplan–
Meier curves suggested that greater tumor prolifera-
tion was associated with a significant reduction in
survival; 5-year cancer-specific survival rates were
58% for those tumors with high Ki-67 expression,
compared with 88% for those with tumors with low
Ki-67 expression (Figure 4, P=0.05).
In a univariate analysis, Ki-67 score, as a contin-
uous variable, as well as age, grade, stage, and
histological type of endometrial cancer, presence or
absence of lymphovascular space invasion and
depth of myometrial invasion, was a prognostic
indicator of cancer-specific survival (Table 4).
A 10% increase in Ki-67 was associated with a
31% (95% CI 7–60%) worsening of cancer-specific
survival. After adjustment for important clinico-
pathological variables and Ki-67 score, only age,
Figure 3 Comparison of different slide preparation and tumor-
sampling techniques. Each point shows the difference between
techniques plotted against the average of the two values. (a) Tissue
microarray vs whole section from same tumor. Significant
discrepancy was noted between tissue microarray and whole
sections scores, with 95% limits of agreement lying at +17% and
−44%. Endometrial cancer specimens were obtained from the
same patient by blinded endometrial sampling performed imme-
diately prior to surgery (pipelle) and after the uterus had been
surgical removed (hysterectomy). (b) Whole slide scoring method.
Significant variation between the two tumor-sampling techniques
was noted using whole slide scoring (95% limits of agreement − 18
to +38%). (c) Hot spot scoring method. In contrast, hot spot scoring
appeared more consistent, with the exception of a single outlier.
Table 2 Comparison of tissue microarray and whole slide scores for matched tumors
Tissue microarray Whole slide
Number of matched tissue microarray and whole slide sections n=67a
Median Ki-67 score (interquartile range) 19% (10–31%) 32% (21–47%)
Number of sections in which the tissue microarray and whole section scores were within 10% of
each other
n=28 (42%)
aTissue microarrays were constructed from the same blocks as those used to cut whole slides and therefore have overlapping areas of tumor.
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stage and histological type of endometrial cancer
remained independent prognostic variables for
cancer-specific survival (Table 3). Ki-67 failed to
reach statistical significance in the multivariate
analysis.
Analyses were repeated using recurrence-free
survival as the outcome of interest and produced
similar results.
Discussion
This is the first study to compare semi-automated
scoring using Definiens Developer software with
manual Ki-67 scoring in endometrial cancer.
Although unable to differentiate between malignant
glands and stromal tissue, when the areas to be
scored were manually selected by observers blinded
to outcome, the accuracy and reproducibility of
scoring by Definiens was extremely high. Automated
scoring was superior to manual scoring in terms of
speed and it was reliable across time and between
scorers.
Compared with whole slide and invasive edge
scoring, hot spot scoring was the most reproducible
scoring method for Ki-67, with excellent intra- and
inter-observer agreement, and the most consistent
across different endometrial tumor-sampling techni-
ques. This is of particular importance for window
studies using Ki-67 as a primary outcome measure,
where an endometrial biopsy taken prior to
intervention is frequently compared with the
hysterectomy specimen at the end of treatment to
determine response.
The scoring of whole slides was found to be
superior to that of tissue microarrays in terms of both
reproducibility and consistency. There are no pub-
lished comparisons of Ki-67 assessment by tissue
microarray and whole slide scoring in the breast
cancer literature for guidance, but the International
Ki-67 in Breast Cancer Working Group do note
anecdotal evidence for lower scoring on tissue
microarrays and advise avoiding their use when
establishing quantitative relationships with clinical










All 179 40 (24–52)





Body mass index (kg/m2) 0.663
o25 22 (12) 44 (26–58)
25–29.9 35 (20) 28 (17–47)
≥ 30 64 (36) 41 (26–51)
Missing data 58 (32) 43 (28–55)
Grade
1 39 (22) 23 (10–39) o0.0001****
2 36 (20) 41 (26–50)
3 104 (58) 44 (30–55)
Stage 0.014**
1 108 (60) 36 (22–50)
2 22 (12) 37 (24–55)
3 42 (24) 44 (29–56)
4 6 (3) 54 (45–67)
Missing data 1 (1) 17 (17–17)
Histological type 0.246
Endometrioid 116 (65) 37 (23–51)




Absent 93 (52) 37 (22–50)
Present 70 (39) 42 (25–55)




o50% 83 (46) 32 (20–50)
≥ 50% 92 (51) 43 (28–53)
Missing data 4 (2) 42 (33–51)
Any adjuvant therapy 0.031*
No 61 (34) 32 (22–49)
Yesb 102 (57) 44 (27–55)
Missing data 16 (9) 35 (26–45)
Ki-67 expression positively correlated with age at the time of surgery,
grade, and stage of endometrial cancer. Higher scores were seen in
tumors with 450% myoinvasion compared with more superficially
invasive cancers and women receiving adjuvant therapy. There was no
association between Ki-67 and body mass index, histological type of
endometrial cancer, and lymphovascular space invasion (P40.05).
aGrade 3 endometrioid tumors are classified within the endometrioid
subtype. Non-endometrioid tumors include serous, clear cell, carci-
nosarcomas, mixed, and undifferentiated cancers.
bAdjuvant treatment included external beam radiotherapy (44, 25%),
vaginal brachytherapy (21, 12%) or both (25, 14%), and/or chemother-
apy (39, 22%), which was single-agent carboplatin (2, 1%) or
carboplatin/paclitaxel-based (29, 16%). Data on chemotherapy regime
absent in 8 (5%) of cases. *p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001.
Figure 4 Cancer-specific survival stratified by Ki-67 expression.
Ki-67 score was divided into two groups using the median score of
40% to denote low (Ki-67 score ≤40%) and high (Ki-67 score
440%) expression. It demonstrated a significant relationship with
cancer-specific survival, with outcome worsening as the Ki-67
score increased. At 5 years, a Ki-67 score ≤40% was associated
with cancer-specific survival rate of 88% compared with 58% for
those with a Ki-67 score 440% (P=0.05).
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outcomes.8 A study in ovarian cancer similarly
showed that Ki-67 staining of tissue microarray cores
may not be representative of the results obtained from
whole section immunohistochemistry.20 Apprecia-
tion of the heterogeneity of staining seen within
whole sections of endometrial tumors is lost when
only a small area is sampled in a core, reflected in the
poor correlation of scores. This becomes even more
evident if there is a time interval between slides being
cut and stained; a delay in staining of more than
6 weeks resulted in lower Ki-67 scores. This has
previously been described for sections stored under
varying conditions; even at 4 °C the resulting hydro-
lysis negatively impacts on antigenicity.21 The
authors, therefore, recommend undertaking staining
on freshly cut sections to avoid this problem and
limiting assessment to whole sections only. If freshly
cut sections are not available, it is important that all
slides are cut at the same time and later stained
together for accurate comparison within a study, with
the caveat that this limits comparability between
studies.
Using the optimized methodology of semi-
automated hot spot scoring, Ki-67 score was strongly
associated with known pathological prognostic vari-
ables, including grade, stage, and depth of myometrial
invasion. Although not independent of other prog-
nostic factors, high Ki-67 was associated with poor
cancer outcomes. These data are consistent with those
of Salvesen et al,22 Stefansson et al,14 Geisler et al,18
and Liu et al,15 who described Ki-67 as a prognostic
biomarker in endometrial cancer, although signifi-
cance was generally lost after adjusting for important
pathological variables like grade of disease and
histological subtype. These studies were considerably
larger than those of Fanning et al17 and Huvila et al,16
who published conflicting results; the latter studies
had fewer disease events, shorter follow-up periods
and were fundamentally underpowered to detect a
significant effect of Ki-67 on cancer-specific outcomes.
Table 4 Univariate and multivariate analysis of associations between Ki-67 score and standard variables and cancer-specific survival in
179 women with endometrial cancer
Variable
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age (1 year) 1.10 1.05–1.15 o0.0001**** 1.06 1.001–1.13 0.028*
Body mass index
o30 kg/m2 1.00 — 0.52 — — —
≥ 30 kg/m2 1.51 0.43–5.25
Grade




1 1.00 — o0.0001**** 1.00 — 0.004**
2 0.96 0.12–7.99 3.27 0.34–31.78
3 7.8 3.03–20.11 6.44 2.07–20.06
4 23.36 6.49–84.05 16.09 2.83–91.36
Histological type
Endometrioid 1.00 — o0.0001**** 1.00 — 0.002**
Non-endometrioid 8.16 3.27–20.39 5.72 1.93–16.95
Lymphovascular space invasion
Absent 1.00 —
Present 4.54 2.21–9.33 o0.0001**** — — —
Depth of myometrial invasion
o50% 1.00 — — — —
≥ 50% 2.46 1.03–5.90 0.043*
Any adjuvant therapy
No 1.00 — 0.202 — — —
Yes 2.05 0.68–6.19
Ki-67 score (10% increase) 1.31 1.07–1.60 0.010** 1.14 0.91–1.41 0.257
Abbreviations: CI, confidence interval; HR, hazard ratio.
Ki-67 was no longer statistically significantly associated with cancer-specific survival when included in the multivariate analysis.
Variables found to be statistically significantly associated with cancer-specific survival in the univariate analysis (P≤0.05) were included in the
multivariate analysis; ‘—’ represents not statistically significant in the multivariate analysis. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Detailed clinical follow-up and expert pathology
review are strengths of this study. The included
population was sufficiently large to ensure that
the study was adequately powered; 10–25 events
are required per prognostic variable under
investigation.19 Meticulous documentation of date
of recurrence and cause of death allowed
cancer-specific and recurrence-free survival to be
calculated, arguably more clinically relevant
endpoints than the overall survival used in other
studies.16,18
The median Ki-67 score was similar to that of other
studies (40% vs 33–40%),14,15,18 who used median
Ki-67 to dichotomize tumors into low and high Ki-67
expression. This approach is crude and prevents
extrapolation across study populations. Ours is the
first study to consider Ki-67 as a continuous variable,
equating a 10% increase in Ki-67 expression with a
cancer-specific survival hazard ratio of 1.31. This
information is important for clinical trials using
Ki-67 as a primary endpoint as it provides some
degree of clinical context in which to interpret the
results. The magnitude of effect seen in this
study is similar to that shown in breast cancer
studies, where Ki-67 expression is routinely log
transformed to normalize the data. In breast cancer,
the hazard ratio per 2.7-fold increase in Ki-67
expression was 1.95 for recurrence-free survival.23
Applying the same methodology to our findings
for ease of comparison, the hazard ratio for
recurrence-free survival in endometrial cancer was
1.94 (95% CI 1.10–3.43).
These findings are unsurprising, given that cancer
is a disorder of unregulated cell proliferation.24
When measured by different methodologies, includ-
ing S-phase fraction by flow cytometry, immunohis-
tochemical staining of proliferative cell nuclear
antigen, Ki-67 or manual counting of mitotic figures,
cell proliferation increases across the spectrum of
endometrial cancer development, from normal
endometrium through to hyperplasia and cancer,
with the highest rates seen in grade 3, serous, and
clear cell cancers.25,26 It is also closely associated
with tumor grade and stage, known important
prognostic variables in endometrial cancer.15,27 It is
logical to hypothesize, therefore, that those
cancers with the greatest cell proliferation will have
the poorest clinical outcome and that the fastest
dividing areas of the tumors (the hot spots) will be
closely associated with disease metastasis and
recurrence.
A limitation of this study was that too few tumors
were available to adequately power the assessment
of Ki-67 in a multivariate analysis, controlling for all
known prognostic clinicopathological variables. The
aim of this study, however, was not to ascertain
whether Ki-67 could replace pathological prognostic
variables, but rather to determine its value as a
primary tissue endpoint for use in clinical trials,
where the window is of treatment is too short to
observe changes in grade and stage of disease. In
breast cancer, a drop in Ki-67 following
short-term treatment with neoadjuvant chemother-
apy predicts long-term response to that drug in the
adjuvant setting.6 Our data suggest that Ki-67 could
be used to stratify patients for entry into endo-
metrial cancer adjuvant drug trials, excluding those
whose prognosis is so good that they are unlikely to
derive benefit from further therapeutic intervention
beyond surgery. This is tentative speculation that
requires formal testing. Ideally, this should include
testing the same novel therapy before and after
surgery and assess changes in pre-surgical Ki-67 score
alongside longer-term cancer-specific and recurrence-
free survival as outcome measures. Response to
treatment could then be stratified according to base-
line Ki-67 score. Such data are clearly required for
drugs like metformin, which is increasingly being
investigated in endometrial cancer window studies, if
there is to be sufficient evidence of clinical efficacy for
them to be used in routine practice.
In conclusion, these data provide evidence that
semi-automated scoring of Ki-67 using Definiens
Developer software is reliable, reproducible, and more
time efficient than manual scoring and that hot spot
methodology should be employed in future clinical
trials as it is the most consistent across endometrial
biopsies and hysterectomy specimens. When
measured using standardized protocols of immuno-
histochemical staining, Ki-67 is associated with endo-
metrial cancer survival and is, therefore, a clinically
relevant endpoint, though further work is required to
determine whether it fulfills all of the criteria to be
used as a biomarker of treatment response.
Acknowledgments
We would like to thank Professor Mitch Dowsett for
his expert guidance and advice regarding study
design. Assistance with slide preparation and opti-
mization of the immunohistochemistry staining
protocol was kindly provided by the Histology
Department at the Cancer Research UK Manchester
Institute. Slide scanning and training in the use of
Definiens Developer software was provided by the
Advanced Imaging Facility at the CRUK Manchester
Institute. VS is funded through a Wellcome Trust/
Wellbeing of Women Research Training Fellowship.
EC and SK are funded through a National Institute
for Health Research (NIHR) Clinician Scientist
Fellowship (award reference NIHR-CS-012–009).
This article presents independent research funded
by the NIHR and facilitated by the Greater Manche-
ster Local Clinical Research Network. The views
expressed are those of the authors and not necessa-
rily those of the NHS, the NIHR or the Department of
Health.
Disclosure/conflict of interest
The authors declare no conflict of interest.
Modern Pathology (2017) 30, 459–468
Ki-67 as a response biomarker in endometrial cancer
S Kitson et al 467
References
1 Cancer Research UK. Uterine (womb) Cancer Incidence




2 Cancer Research UK. Uterine Cancer Mortality Statis-




3 Cancer Research UK. CRUK Prognostic/Predictive
Biomarker (BM) Roadmap, Available at http://www.
cancerresearchuk.org/prod_consump/groups/cr_com
mon/@fre/@fun/documents/generalcontent/cr_027486.
pdf (accessed 4 December 2015).
4 Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for
estrogen receptor-positive breast cancer based on
postneoadjuvant endocrine therapy tumor characteris-
tics. J Natl Cancer Inst 2008;100:1380–1388.
5 de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as
prognostic marker in early breast cancer: a meta-
analysis of published studies involving 12,155 patients.
Br J Cancer 2007;96:1504–1513.
6 Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes
in Ki-67 during neoadjuvant treatment of primary
breast cancer with anastrozole or tamoxifen alone or
combined correlate with recurrence-free survival. Clin
Cancer Res 2005;11:951s–958s.
7 Scholzen T, Gerdes J. The Ki-67 protein: from the
known and the unknown. J Cell Physiol 2000;182:
311–322.
8 Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of
Ki67 in breast cancer: recommendations from the
international Ki67 in Breast Cancer working group.
J Natl Cancer Inst 2011;103:1656–1664.
9 Mitsuhashi A, Kiyokawa T, Sato Y, et al. Effects of
metformin on endometrial cancer cell growth in vivo: a
preoperative prospective trial. Cancer 2014;120:
2986–2995.
10 Laskov I, Drudi L, Beauchamp MC, et al. Anti-diabetic
doses of metformin decrease proliferation markers in
tumors of patients with endometrial cancer. Gynecol
Oncol 2014;134:607–614.
11 Schuler KM, Rambally BS, DiFurio MJ, et al.
Antiproliferative and metabolic effects of metformin
in a preoperative window clinical trial for
endometrial cancer. Cancer Med 2015;4:161–173.
12 Sivalingam VN, Kitson S, McVey R, et al. Measuring
the biological effect of presurgical metformin treatment
in endometrial cancer. Br J Cancer 2016;114:281–289.
13 Thangavelu A, Hewitt MJ, Quinton ND, et al. Neoadju-
vant treatment of endometrial cancer using anastrozole:
a randomised pilot study. Gynecol Oncol 2013;131:
613–618.
14 Stefansson IM, Salvesen HB, Immervoll H, et al.
Prognostic impact of histological grade and vascular
invasion compared with tumour cell proliferation in
endometrial carcinoma of endometrioid type. Histo-
pathology 2004;44:472–479.
15 Liu T, Gao H, Yang M, et al. Correlation of TNFAIP8
overexpression with the proliferation, metastasis, and
disease-free survival in endometrial cancer. Tumour
Biol 2014;35:5805–5814.
16 Huvila J, Talve L, Carpen O, et al. Progesterone receptor
negativity is an independent risk factor for relapse
in patients with early stage endometrioid endo-
metrial adenocarcinoma. Gynecol Oncol 2013;130:
463–469.
17 Fanning J, Brown S, Phibbs G, et al. Immunohisto-
chemical evaluation is not prognostic for recurrence in
fully staged high-risk endometrial cancer. Int J Gynecol
Cancer 2002;12:286–289.
18 Geisler JP, Geisler HE, Miller GA, et al. MIB-1
in endometrial carcinoma: prognostic significance
with 5-year follow-up. Gynecol Oncol 1999;75:
432–436.
19 Altman DG, McShane LM, Sauerbrei W, et al. Report-
ing recommendations for tumor marker prognostic
studies (REMARK): explanation and elaboration. PLoS
Med 2012;9:e1001216.
20 Khouja MH, Baekelandt M, Sarab A, et al. Limitations
of tissue microarrays compared with whole sections in
survival analysis. Oncol Lett 2010;5:827–831.
21 Economou M, Schoni L, Hammer C, et al. Proper
paraffin slide storage is crucial for translational
research projects involving immunohistochemistry
stains. Clin Transl Med 2014;3:4.
22 Salvesen HB, Iversen OE, Akslen LA. Prognostic
significance of angiogenesis and Ki-67, p53, and p21
expression: a population-based endometrial carci-
noma study. J Clin Oncol 1999;17:1382–1390.
23 Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of
Ki67 expression after short-term presurgical endocrine
therapy for primary breast cancer. J Natl Cancer Inst
2007;99:167–170.
24 Hanahan D, Weinberg RA. The hallmarks of cancer.
Cell 2000;100:57–70.
25 Ito K, Sasano H, Watanabe K, et al. Immunohistochem-
ical study of PCNA (proliferating cell nuclear antigen)
in normal and abnormal endometrium. Int J Gynecol
Cancer 1993;3:122–127.
26 Morsi HM, Leers MP, Jager W, et al. The patterns of
expression of an apoptosis-related CK18 neoepitope,
the bcl-2 proto-oncogene, and the Ki67 proliferation
marker in normal, hyperplastic, and malignant
endometrium. Int J Gynecol Pathol 2000;19:118–126.
27 Prat J. Prognostic parameters of endometrial
carcinoma. Hum Pathol 2004;35:649–662.
This work is licensed under a Creative
Commons Attribution 4.0 International
License. The images or other third party material in
this article are included in the article’s Creative
Commons license, unless indicated otherwise in the
credit line; if the material is not included under the
Creative Commons license, users will need to obtain
permission from the license holder to reproduce the
material. To view a copy of this license, visit http://
creativecommons.org/licenses/by/4.0/
© The Author(s) 2017
Modern Pathology (2017) 30, 459–468
Ki-67 as a response biomarker in endometrial cancer
468 S Kitson et al
